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Abstract
Introduction: Previous studies have shown that traditional risk factors such as hypercholesterolemia and
hypertension account for only a small proportion of the dramatically increased risk of atherosclerotic coronary
artery disease (CAD) in systemic lupus erythematosus (SLE). However, in these studies, exposure to risk factors was
measured only at baseline. In this study, our objective was to compare measures of cumulative exposure with
remote and recent values for each of total cholesterol (TC), systolic (SBP), and diastolic (DBP) blood pressure in
terms of ability to quantify risk of atherosclerotic CAD in patients with SLE.
Methods: Patients in the Toronto lupus cohort had TC and BP measured at each clinic visit and were followed
up prospectively for the occurrence of CAD. For each patient, arithmetic mean, time-adjusted mean (AM) and
area-under-the-curve (AUC) were calculated for serial TC, SBP, and DBP measurements. Proportional hazards
regression models were used to compare these summary measures with recent and first-available ("remote”)
measurements in terms of ability to quantify risk of CAD events, defined as myocardial infarction, angina, or
sudden cardiac death.
Results: The 991 patients had a mean ± SD of 19 ± 19 TC measurements per patient. Over a follow-up of 6.7 ±
6.4 years, 86 CAD events occurred; although remote TC was not significantly predictive of CAD, mean and AM
TC were more strongly predictive (hazard ratio (HR) 2.07; P = 0.003) than recent TC (HR 1.86, P = 0.001). AUC TC
was not predictive of CAD. A similar pattern was seen for DBP and SBP. Older age, male sex, higher baseline
and recent disease activity score, and corticosteroid use also increased CAD risk, whereas antimalarials were
protective.
Conclusions: In contrast to the population-based Framingham model, first-available TC and BP are not predictive
of CAD among patients with SLE, in whom measures reflecting cumulative exposure over time are better able to
quantify CAD risk. This is an important consideration in future studies of dynamic risk factors for CAD in a chronic
relapsing-remitting disease such as SLE. Our findings also underpin the importance of adequate control of SLE
disease activity while minimizing corticosteroid use, and highlight the cardioprotective effect of antimalarials.
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Systemic lupus erythematosus (SLE) is associated with a
dramatically increased risk of atherosclerotic coronary
artery disease (CAD), such that women with SLE aged
34 to 44 years are more than 50 times more likely to
develop myocardial infarction (MI) than are age-
matched peers [1]. Traditional risk factors measured at
baseline, as defined in the Framingham model, do not
fully account for this increased risk [2].
In the general population, it has been shown that
recent and remote blood pressure (BP) predict cardio-
vascular risk incrementally over current BP [3]. In an
inception cohort of patients with SLE, those with sus-
tained hypercholesterolemia in the first 3 years of their
disease were shown to be at greatest risk of cardiovascu-
lar events over 12 to 14 years of follow-up, compared
with those who had persistently normal cholesterol or
“variable” hypercholesterolemia in the first 3 years of
disease [4]. We previously showed that both TC and BP
take a variable course in patients with SLE and that
almost half of the total variance over time in both TC
and BP is seen within rather than between patients [5].
T h e s ef i n d i n g ss u g g e s tt h a tt h er i s ko ff u t u r ec o r o n a r y
events might be best quantified by using strategies that
take into account multiple measurements of risk factors
over time.
In this prospective proof-of-concept cohort study, we
sought to compare “summary measures” of cumulative
exposure to TC, SBP, and DBP, with single-point-in-
time measurements of these risk factors (both recent
and remote), in terms of ability to quantify CAD risk.
Materials and methods
Patients
Patients attending the University of Toronto lupus
clinic are routinely seen at 2- to 6-monthly intervals
wherein clinical and laboratory data, including TC, sys-
tolic blood pressure (SBP), and diastolic blood pressure
(DBP) levels are obtained and recorded according to a
set protocol. Patients are followed up prospectively for
the occurrence of CAD events. In this study, we
included patients who had two or more measurements
of TC, SBP, and DBP taken before a CAD event (or
last visit), in whom the gap between measurements did
not exceed 18 months. Patients with a history of CAD
before the start of the study were excluded. All
patients fulfilled four or more of the American College
of Rheumatology classification criteria for SLE, or had
three criteria and a typical lesion of SLE on skin or
renal biopsy [6,7]. Informed consent was obtained
from all participants, and the study was approved by
the research ethics board of the University Health
Network.
Methods
Measurement of TC, SBP, and DBP
Each measurement of TC, SBP, and DBP was tied to a
clinic visit. TC was measured in plasma by using a com-
mercial assay (Boehringer Mannheim kit 236691, India-
napolis, IN, USA) and recorded in millimoles per liter.
As only small, clinically insignificant differences in TC
are found when measured in the fasting or nonfasting
state, nonfasting samples were used [8]. SBPs and DBPs
were measured in millimeters of mercury (mm Hg) at
every visit by using a manual sphygmomanometer. The
patient was allowed to rest for 5 minutes in the sitting
position. The reading was taken on the right arm, sup-
ported at the level of the heart. Korotkoff phase V (dis-
appearance) was recorded as DBP.
Calculation of “summary measures” of TC, SBP, and DBP
For each of TC, SBP, and DBP, an arithmetic mean of
all available measurements in each patient was calcu-
lated as the sum of all individual measurements divided
by the total number of measurements. In each patient,
for each of TC, SBP, and DBP, a time-adjusted mean
(AM) was also calculated by using the formula:
n 
i=2
xi + xi−1
2

ti
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where xi i st h el e v e lo ft h ev a r i a b l ea tv i s i tI ,a n dt i is
the time interval between visit i and i-1. By incorporat-
ing the time interval between measurements in its calcu-
lation, the AM takes into account the length of time
that TC, SBP, and DBP are presumed to have remained
at a particular level. The arithmetic mean and AM were
reported in millimoles per liter for TC and millimeters
of mercury for SBP and DBP. In each patient, for each
of TC, SBP, and DBP, the area-under-the-curve (AUC)
was calculated by using integral calculus. AUC is
reported in millimoles per liter multiplied by t and milli-
meters mercury multiplied by t for each of TC and BP,
respectively, where t is the unit of time, in this case,
months. For any given visit (Vi), the summary measure
for each of TC, SBP, and DBP was calculated from the
f i r s ts t u d yv i s i t( V 1) up to and including the visit before
(Vi-1), thus ensuring that for all time intervals, exposure
preceded outcome. The last visit (VL) was either a visit
at which a CAD event was recorded or the last clinic
visit as of August 2008 in those who remained CAD
free.
Covariates
Covariates included in the proportional hazards models
were sex, age, disease duration, disease-activity score
(Systemic Lupus Erythematosus Disease Activity Index
2000; SLEDAI-2K), anti-phospholipid antibodies, “other”
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ing), medications including corticosteroids, antimalarials,
immunosuppressives, antihypertensives, and lipid-lower-
ing therapy (statins), all recorded at baseline, and at
each and every visit. Age and disease duration (from
diagnosis to Vi) were reported in years. SLEDAI-2K is
an organ-weighted index of disease activity, scored from
0 to 105, with higher scores indicating more-active dis-
ease [9]. Antimalarials included chloroquine and hydro-
xychloroquine. Immunosuppressives included
methotrexate, azathioprine, mycophenolate mofetil,
cyclosporine, and cyclophosphamide. Antihypertensives
included diuretics, b-blockers, calcium channel blockers,
angiotensin-converting enzyme inhibitors, and angioten-
sin type II receptor blockers. The cumulative corticos-
teroid dose over the period of follow-up from study
entry (V1) to the last visit (VL) was calculated and
reported in grams. Use of all other medications was
reported categorically at each visit, irrespective of dose.
Diabetes was defined as fasting plasma glucose > 7.0
mmol/L or diabetes therapy ever. Current smoking was
defined as smoking an average of one or more cigarette/
s per day in the past month.
Outcome variables
CAD events were angina pectoris, myocardial infarction
(MI), and sudden cardiac death. MI was defined as one
of definite electrocardiographic (ECG) abnormalities, or
typical symptoms with probable ECG abnormalities and
abnormal enzymes (≥2 times upper limit of normal), or
typical symptoms and abnormal enzymes. Angina pec-
toris was defined as severe pain or discomfort over the
u p p e ro rl o w e rs t e r n u mo ra n t e r i o rl e f tc h e s ta n dl e f t
arm, of short duration, relieved by rest or vasodilators
in the absence of active SLE, or in the presence of ather-
osclerotic vascular disease elsewhere (for example, ather-
osclerotic peripheral vascular or cerebrovascular
disease). The diagnosis of angina and MI required con-
firmation by a cardiologist. Sudden cardiac death was
defined as death with undetermined cause but presumed
cardiac.
A CAD event that occurred between Vi and Vi+1 was
recorded at Vi+1. For patients who had more than one
CAD event, only the first was used in analysis. Some
patients may have had both angina and MI recorded for
the first time at a particular visit; this was treated as
only one event rather than two.
Univariate comparisons
For each of the TC and BP models, univariate compari-
sons of demographic, disease- and treatment-related
variables and traditional cardiac risk factors in patients
who had CAD events and those that remained CAD
free were performed by using t tests for continuous vari-
ables and c
2 tests for categoric variables. In case of non-
normally distributed data, Mann-Whitney U tests were
used for continuous variables. Two-sided P values (P) ≤
0.05 were considered to be significant.
Time-constant regression models
For each of TC, SBP, and DBP, two time-constant pro-
portional hazards models were run. Variables in the first
model included first available (baseline) measurement of
T C( o rS B P ,D B P ) ,a l o n gw i t hs e x ,a g e ,S L E D A I - 2 K
score at study entry (V1 or “baseline”), and anti-phos-
pholipid antibodies, diabetes, smoking, corticosteroid,
antimalarial, immunosuppressive, antihypertensive, and
lipid-lowering medication use “ever” from V1 to VL-1.
The second model included the average (arithmetic
mean) of the first two available measurements of TC (or
SBP or DBP) and all covariates included in the first Cox
model.
Time-dependent regression models
For each of TC, SBP, and DBP, we also ran four time-
dependent proportional hazards regression models. In
the first model, recent measurements of TC (or SBP or
DBP) were used in a dynamic manner, varying from
visit to visit. In the remaining three models, summary
measures (mean, AM, AUC) were used in a time-depen-
dent manner (that is, updated from visit to visit). Cov-
ariates in these models included sex, age, SLEDAI-2K
score, anti-phospholipid antibodies, diabetes, smoking,
corticosteroid, antimalarial, immunosuppressive, anti-
hypertensive and lipid-lowering medication use, also
treated in a time-dependent fashion (that is, updated
f r o mv i s i tt ov i s i t ) .F o re a c ho fT C ,S B P ,a n dD B Pa t
each visit, single point, mean, and AM measurements
were strongly correlated. Therefore, each summary mea-
sure was analyzed in a separate model.
Both time-constant and time-dependent models are
reported as hazard ratios (HRs) with accompanying 95%
confidence interval (95% CI) and P value, for each of
the predictor variables and covariates. All statistical ana-
lyses were performed by using the SAS software version
9.1 (SAS Institute, Inc., Cary, NC, U.S.A.).
Results
Characteristics of the patients in this study are pre-
sented in Table 1. Overall, the BP dataset contained 991
patients, whereas the TC dataset comprised 956
patients. In each dataset, patients were mostly female
(88%) and mostly Caucasian (70%). A total of 94 coron-
ary events occurred (75 angina, 25 MI, and two sudden
cardiac deaths; eight had both angina and MI) in the BP
dataset, whereas the TC dataset contained 86 coronary
events (71 angina, 20 MI, and two sudden cardiac
deaths; seven had both angina and MI). The mean ± SD
a g ea n dd i s e a s ed u r a t i o na te n t r yi n t ot h es t u d yw e r e
very similar for both datasets (37.1 ± 14.0 and 6.1 ± 7.9
years, respectively, for the BP dataset). Likewise, mean ±
SD SLEDAI-2K score and Systemic Lupus
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American College of Rheumatology Damage Index
(SLICC/ACR-DI) at study entry were similar in the two
datasets (9.2 ± 7.5 and 0.5 ± 1.2, respectively, for the BP
dataset), indicating moderate d i s e a s ea c t i v i t ya n dm i n i -
mal disease-related damage [10]. For each dataset, at
entry into the study, more than 60% of patients were
taking corticosteroids, whereas approximately 40% were
taking antimalarials, and 25% were taking immunosup-
pressives. In each dataset, at the start of the study,
approximately 22% of patients were hypertensive, 40%
had hypercholesterolemia, 3% had diabetes, and 19%
were smokers. At study start, in each dataset, 25% were
taking antihypertensives, and 5% were taking lipid-low-
ering medications.
Summary measures for BP
The calculation of summary measures was based on 19,
579 individual measurements of SBP and DBP, with a
mean ± SD of 20 ± 20 (median, 13) serial measurements
per patient. The mean ± SD (median) time interval
between measurements was 4.2 ± 2.3 (3.4) months. The
mean ± SD (median) time from study start to the visit
before a CAD event (or last clinic visit) was 6.5 ± 6.7
(4.2) years. The mean ± SD (median) length of follow-
up from study start to CAD event (or last clinic visit)
was 7.0 ± 6.7 (4.6) years. Among all patients, the mean
SBP at the start of study was 123.9 ± 19.4 mm Hg,
whereas the mean DBP at the start of study was 77.6 ±
12.3 mm Hg.
Summary measures for TC
The calculation of summary measures was based on 17,
936 individual measurements of TC, with a mean ± SD
of 19 ± 19 (median, 12) serial measurements per patient.
The mean ± SD (median) time interval between TC
measurements was 4.3 ± 2.3 (3.6) months. The mean ±
SD (median) time from study start to the visit before a
CAD event (or last clinic visit) was 6.3 ± 6.4 (4.2) years.
The mean ± SD (median) length of follow-up from
study start to CAD event (or last clinic visit) was 6.7 ±
6.4 (4.6) years. Among all patients, the mean TC level at
the start of study was 5.3 ± 1.6 mmol/L.
Univariate comparisons
Univariate comparisons of patients with and without a
CAD event for each of the BP and TC models are pre-
sented in Table 2. In the BP models, patients who
experienced CAD events were more likely to be Cauca-
sian (87.2% versus 68.6%; P = 0.004), older (46.0 ± 13.2
versus 36.6 ± 13.9 years; P < 0.0001), menopausal
(44.4% versus 23.7%; P = 0.0001), hypertensive (31.0%
versus 14.4%; P < 0.0001), and taking corticosteroids
Table 1 Patient characteristics
BP Dataset TC Dataset
n (%) or mean ±
SD
n (%) or mean ±
SD
Number of patients 991 956
Female 879 (88.7%) 849 (88.8%)
Race
Caucasian 70% 70%
Black 11% 11%
Asian 11% 11%
Other 8% 8%
CAD events
MI
Angina
25
75
20
71
Sudden cardiac death 2 2
Total 94 86
Age
a
At diagnosis 31.0 ± 13.8 30.9 ± 13.8
At study entry 37.1 ± 14.0 37.5 ± 14.1
Disease duration
a
At first clinic visit 4.0 ± 5.8 4.0 ± 5.9
At study entry 6.1 ± 7.9 6.6 ± 8.1
SLEDAI-2K
b
At first clinic visit 9.7 ± 7.7 9.6 ± 7.7
At study entry 9.2 ± 7.5 8.3 ± 7.2
SLICC/ACR-DI
c
At first clinic visit 0.3 ± 0.7 0.3 ± 0.7
At study entry 0.5 ± 1.2 0.6 ± 1.2
Steroids at study entry 623 (63%) 625 (65.6%)
Antimalarials at study entry
d 380 (38.5%) 385 (40.4%)
Immunosuppressives
e
At study entry 235 (23.8%) 233 (24.5%)
Hypertension at study entry
f 221 (22.3%) 212 (22.6%)
Hypercholesterolemia at study
entry
g
344 (41.8%) 408 (42.7%)
Diabetes at study entry
h 28 (2.9%) 31 (3.3%)
Smoker at study entry
i 190 (19.5%) 183 (19.5%)
Antihypertensive use
at study entry
j 174/691 (25.2%) 174/699 (24.9%)
Lipid-lowering meds
at study entry
k 23/440 (5.2%) 22/440 (5.0%)
BP, blood pressure (mm Hg); CAD, coronary artery disease; MI, myocardial
infarction; SD, standard deviation; SLEDAI-2K, Systemic Lupus Erythematosus
Disease Activity Index 2000; SLICC/ACR-DI, Systemic Lupus International
Collaborating Clinics/American College of Rheumatology Damage Index; TC,
total plasma cholesterol (mmol/L).
aYears.
bScores range from 0 to 105, with
higher scores indicating more-active disease.
cScores range from 0 to 46, with
higher scores indicating greater disease-related damage.
dAntimalarials
include chloroquine and hydroxychloroquine.
eImmunosuppressives include
methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, and
cyclophosphamide.
fDiastolic BP ≥90 or systolic BP ≥140 mm Hg or treatment
with antihypertensive medication.
gHypercholesterolemia was defined as
cholesterol > 5.2 mmol/L or lipid-lowering therapy.
hDiabetes was defined as
fasting plasma glucose > 7.0 mmol/L or diabetes therapy.
iCurrent smoking is
defined as smoking an average of one or more cigarettes per day over the
past month.
jAll classes of antihypertensives including diuretics, b-blockers,
calcium channel blockers, angiotensin-converting enzyme inhibitors, and
angiotensin type II receptor blockers.
kHMG Co-A reductase inhibitors (statins)
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BP models TC models
CAD (n = 94) No CAD (n = 897) CAD (n = 86) No CAD (n = 870)
n(%) or mean ±
SD
n(%) or mean ±
SD
Pn (%) or mean ±
SD
n(%) or mean ±
SD
P
Female 72 (83.7%) 777 (89.3%) 0.12 78 (83.0%) 801 (89.3%) 0.07
Menopause
a at study start 32 (44.4%) 184 (23.7%) 0.0001 33 (42.3%) 189 (23.6%) 0.0003
Race
Caucasian 75 (87.2%) 574 (68.6%) 0.004 81 (86.2%) 593 (68.7%) 0.005
Black 3 (3.5%) 96 (11.5%) 4 (4.3%) 97 (11.2%)
Asian 4 (4.7%) 94 (11.2.%) 4 (4.3%) 97 (11.2%)
Other 4 (4.7%) 73 (8.7%) 5 (5.3%) 76 (8.8%)
Disease duration
b
At first visit 4.08 ± 5.71 4.01 ± 5.87 0.92 4.24 ± 5.72 3.94 ± 5.80 0.63
At study start 6.99 ± 7.84 6.54 ± 8.17 0.62 5.95 ± 7.23 6.13 ± 8.00 0.83
SLEDAI-2K
c
At first visit 12.34 ± 8.67 9.49 ± 7.63 0.001 12.16 ± 8.63 9.60 ± 7.65 0.002
At study start 9.59 ± 7.99 8.28 ± 7.26 0.11 11.36 ± 8.86 9.02 ± 7.50 0.02
Disease manifestations
d
ever from diagnosis to first visit
Musculoskeletal 42 (44.7%) 365 (40.7%) 0.45 44 (51.2%) 363 (41.7%) 0.09
Cutaneous 69 (73.4%) 504 (56.2%) 0.001 65 (75.6%) 507 (58.3%) 0.002
Renal 46 (48.9%) 364 (40.6%) 0.12 47 (54.7%) 370 (42.5%) 0.03
Nervous system 32 (34.0%) 180 (20.1%) 0.002 32 (37.2%) 189 (21.7%) 0.001
Hematologic 13 (13.8%) 110 (12.3%) 0.66 14 (16.3%) 117 (13.5%) 0.47
Vasculitis 19 (20.2%) 126 (14.1%) 0.11 19 (22.1%) 133 (15.3%) 0.10
Immunologic 58 (61.7%) 640 (71.4%) 0.05 62 (72.1%) 637 (73.2%) 0.82
Serosal 13 (13.8%) 77 (8.6%) 0.09 11 (12.8%) 74 (8.5%) 0.18
Fever 16 (17.0%) 141 (15.7%) 0.74 18 (20.9%) 138 (15.9%) 0.23
Disease manifestations
e ever during follow-
up
Musculoskeletal 70 (74.5%) 508 (56.6%) 0.0008 67 (77.9%) 476 (54.7%) < 0.0001
Cutaneous 82 (87.2%) 643 (71.7%) 0.001 73 (84.9%) 615 (70.7%) 0.005
Renal 72 (76.6%) 581 (64.8%) 0.02 62 (72.1%) 547 (62.9%) 0.09
Nervous system 58 (61.7%) 304 (33.9%) < 0.0001 53 (61.6%) 284 (32.6%) < 0.0001
Hematologic 25 (26.6%) 229 (25.5%) 0.82 22 (25.6%) 214 (24.6%) 0.84
Vasculitis 42 (44.7%) 207 (23.1%) < 0.0001 36 (41.9%) 189 (21.7%) < 0.0001
Immunologic 82 (87.2%) 769 (85.7%) 0.69 76 (88.4%) 741 (85.2%) 0.42
Serosal 22 (23.4%) 112 (12.5%) 0.003 19 (22.1%) 94 (10.8%) 0.002
Fever 42 (44.7%) 231 (25.8%) < 0.0001 40 (46.5%) 200 (23.0%) < 0.0001
Chronic renal insufficiency ever
f 5 (5.3%) 64 (7.1%) 0.51 4 (4.7%) 60 (6.9%) 0.43
Anti-phospholipid antibodies
g
Ever from first clinic visit to last visit 69 (75.8%) 546 (61.1%) 0.006 66 (76.7%) 527 (60.8%) 0.004
Ever in the study period 66 (72.5%) 491 (55.0%) 0.001 61 (70.9%) 459 (53.0%) 0.001
Corticosteroids
At study start 66 (76.7%) 559 (68.5%) 0.02 66 (70.2%) 557 (62.2%) 0.13
Ever during follow-up 81 (94.2%) 676 (77.7%) 0.0003 88 (93.6%) 706 (78.7%) 0.0006
Cumulative steroid dose (g)
From first clinic visit to last visit 42.3 ± 34.4 31.7 ± 34.7 0.006 43.5 ± 34.6 31.9 ± 35.1 0.005
In the study period 30.3 ± 25.8 20.5 ± 23.1 0.0002 28.8 ± 25.1 19.7 ± 21.9 0.0005
Antimalarials
g
At study start 29 (33.7%) 356 (41.1%) 0.18 31 (33.0%) 349 (39.0%) 0.25
Ever during follow-up 51 (59.3%) 622 (71.5%) 0.02 58 (61.7%) 639 (71.2%) 0.05
Immunosuppressives
h
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Patients with CAD events were also more likely to have
been older at lupus diagnosis (39.0 ± 14.1 versus 30.1 ±
13.5 years; P < 0.0001) and to have anti-phospholipid
antibodies (75.8% versus 61.1%; P = 0.006), hypertension
(82.6% versus 43.7%; P < 0.0001), hypercholesterolemia
(91.9% versus 68.6%; P < 0.0001), and diabetes mellitus
(15.1% versus 6.7%; P = 0.005) during follow-up, than
were those who remained CAD free. In addition, they
were more likely to be treated with corticosteroids
(94.2% versus 77.7%; P = 0.0003) at higher cumulative
doses (42.3 ± 34.4 versus 31.7 ± 34.7 g; P = 0.006),
Table 2 Univariate comparison of patients with and without CAD used in TC and BP models (Continued)
At study start 16 (18.6%) 217 (25.1%) 0.18 14 (15.1%) 221 (24.8%) 0.04
Ever during follow-up 46 (53.5%) 454 (52.2%) 0.82 51 (54.3%) 471 (52.5%) 0.75
Hypertension
i
At study start 26 (31.0%) 123 (14.4%) < 0.0001 26 (27.7%) 131 (14.6%) 0.001
Ever during follow-up 71 (82.6%) 380 (43.7%) < 0.0001 77 (81.9%) 403 (44.9%) < 0.0001
Hypercholesterolemia
j
At study start 26 (31.0%) 350 (40.2%) < 0.0001 39 (65.0%) 305 (39.9%) 0.0001
Ever during follow-up 79 (91.9%) 597 (68.6%) < 0.0001 81 (91.0%) 614 (69.1%) < 0.0001
Diabetes mellitus
k
At study start 5 (6.0%) 29 (3.4%) 0.22 4 (4.4%) 27 (3.1%) 0.52
Ever during follow-up 13 (15.1%) 58 (6.7%) 0.005 13 (13.8%) 61 (6.8%) 0.01
Smoker
l
At study start 20 (23.8%) 162 (19.0%) 0.28 23 (25.0%) 166 (18.8%) 0.15
Ever during follow-up 27 (31.4%) 220 (25.4%) 0.22 30 (31.9%) 229 (25.6%) 0.18
Antihypertensives
m
Ever up to study start 14/37 (37.8%) 166/642 (25.9%) 0.11 16/39 (41.0%) 169/654 (25.8%) 0.04
Ever during follow-up 69/76 (90.8%) 355/487 (72.9%) 0.0008 71/83 (85.5%) 361/506 (71.3%) 0.007
Lipid-lowering medications
n
Ever up to study start 1/10 (10.0%) 26/427 (6.1%) 0.48 1/11 (9.1%) 27/430 (6.3%) 0.52
Ever during follow-up 47/76 (61.8%) 144/543 (26.5%) < 0.0001 48/70 (68.6%) 145/528 (27.5%) < 0.0001
TC level at study start
o 5.85 ± 1.62 5.19 ± 1.56 0.0002
Mean of first two TC levels
o 5.91 ± 1.53 5.19 ± 1.49 < 0.0001
Mean of all TC levels
o 5.72 ± 1.23 4.95 ± 1.11 < 0.0001
AM of all TC levels
o 5.72 ± 1.23 4.94 ± 1.11 < 0.0001
AUC of all TC levels
p 15, 806 ± 13, 063 11, 117 ± 11, 976 0.0006
SBP at study start
o 131.65 ± 21.29 123.11 ± 19.08 < 0.0001
Mean of first two SBPs
o 132.45 ± 19.00 123.03 ± 17.35 < 0.0001
Mean of all SBPs
o 134.90 ± 15.32 121.96 ± 14.81 < 0.0001
AM of all SBPs
o 134.68 ± 15.351 121.88 ± 14.99 < 0.0001
AUC of all SBPs
∞p 400, 217 ± 318,
056
285, 335 ± 304,
573
0.0006
DBP at study start
o 77.3 ± 12.3 80.8 ± 11.8 0.009
Mean of first two DBPs
o 77.2 ± 10.5 82.0 ± 10.5 < 0.0001
Mean of all DBPs
o 76.2 ± 8.5 82.7 ± 6.7 < 0.0001
AM of all DBPs
o 76.2 ± 8.6 82.6 ± 6.8 < 0.0001
AUC of all DBPs
p 179, 476 ± 192,
071
245, 236 ± 194,
324
0.002
AM, time-adjusted mean; AUC, area-under-the-curve; CAD, coronary artery disease; DBP, diastolic blood pressure; SBP, systolic blood pressure; SLEDAI-2K,
Systemic Lupus Erythematosus Disease Activity Index 2000; TC, total plasma cholesterol (mmol/L).
aMenopause defined as a minimum of 12 months of
amenorrhea irrespective of cause.
bYears.
cScores range from 0 to 105, with higher scores indicating more-active disease.
dDisease manifestations defined based
on SLEDAI-2K definitions.
eChronic renal insufficiency defined based on SLICC/ACR DI definition (glomerular filtration rate < 50%, proteinuria ≥3.5 g/24 h, or end-
stage renal disease).
fMeasured by using commercial assays, with test reported positive if either IgM or IgG antibody level exceeded manufacturer-recommended
cut points.
gAntimalarials include chloroquine and hydroxychloroquine.
hImmunosuppressives include methotrexate, azathioprine, mycophenolate mofetil,
cyclosporine, and cyclophosphamide.
iHypertension was defined as DBP ≥90 or SBP ≥140 mm Hg or treatment with antihypertensive medication.
jHypercholesterolemia was defined as TC > 5.2 mmol/L or lipid-lowering therapy.
kDiabetes was defined as fasting plasma glucose > 7.0 mmol/L or diabetes
therapy.
lCurrent smoking is defined as smoking of an average of one or more cigarettes per day over the past month.
mAll classes of antihypertensives
including diuretics, b-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin type II receptor blockers.
nHMG Co-A
reductase inhibitors (statins).
ommol/L.
pmmol/L multiplied by months.
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Page 6 of 14antihypertensives (90.8% versus 72.9%; P = 0.0008), and
lipid-lowering medications (61.8% versus 26.5%; P <
0.0001) during follow-up. Patients with CAD events
were less likely to have been exposed to antimalarials
during follow-up (59.3% versus 71.5%; P = 0.02).
In the TC models, univariate comparison of patients
with and without CAD outcomes revealed results that
were similar to the BP models (Table 2). TC level at
study start (5.85 ± 1.62 versus 5.19 ± 1.56 mmol/L; P =
0.0002), average of first two TC levels (5.91 ± 1.53 versus
5.19 ± 1.49 mmol/L; P < 0.0001), and mean (5.72 ± 1.23
versus 4.95 ± 1.11 mmol/L; p < 0.0001), AM (5.72 ± 1.23
versus 4.94 ± 1.11; P < 0.0001), and AUC (15, 806 ± 13,
063 versus 11, 1117 ± 11, 976 mmol/L; P = 0.0006) of all
serial TC levels were higher in patients who had CAD
events than in those who remained CAD free.
In both the BP and TC datasets, patients with CAD
events were more likely to have musculoskeletal, cuta-
neous, renal, and nervous system manifestations of
lupus and were also more likely to have vasculitis, sero-
sitis, and fever during the course of their disease. How-
ever, no difference was found in the prevalence of
chronic renal insufficiency, based on SLICC/ACR DI
definition [10], among those with and without CAD
(5.3% versus 7.1%; P = 0.51 in the BP dataset).
Proportional hazards multiple regression models
TC models
Table 3 shows the results of the proportional hazards
models for CAD events by using various measures of
TC. In the time-constant models (columns 1 and 2),
neither first-available ("remote”) TC nor the average of
first two TC levels was significantly associated with a
C A De v e n t .H o w e v e r ,i nt h e s em o d e l s ,m a l es e x( H R=
2.02; P = 0.02), age (HR = 1.06; P < 0.0001), and SLE-
DAI-2K (HR = 1.03; P = 0.04) at study start (baseline),
and steroid use ever (HR = 4.17; P = 0.003) were signifi-
cantly associated with a CAD event. Antimalarial use
ever was protective against CAD (HR = 0.50; P = 0.003).
In time-dependent models (Table 3, columns 3 to 5,
inclusive), most recent (HR = 1.22; P =0 . 0 1 ) ,mean (HR
= 1.22; p = 0.04) and AM (HR = 1.22; p = 0.03) TC at
each visit were significantly associated with CAD event.
When only the significant covariates were included in
the models (Table 4), mean and AM TC were more
strongly predictive of CAD (HR = 2.07; P = 0.003 for
both) than was recent TC (HR = 1.86; P = 0.001). In
these models, other significant covariates included male
sex (HR = 1.84; P =0 . 0 4 ,i nrecent TC model), age (HR
=1 . 0 6 ;P < 0.0001 for all three models), SLEDAI-2K
score (HR = 1.09; P < 0.0001 for all three models), ster-
oid use (HR = 1.85 and 1.89 for mean and AM TC, P =
0.03 for all three models) and hypertension at each visit
(HR = 1.57; P = 0.06 for both mean and AM TC
models). AUC TC (Table 3, last column) was not signifi-
cantly associated with CAD.
SBP models
Results of the proportional hazards models for CAD
outcomes by using various measures of systolic blood
pressure (SBP) are presented in Table 5. In the time-
constant models (columns 1 and 2), neither first avail-
able (remote) SBP nor the average of first two SBPs was
associated with a CAD event. However, in these models,
male sex (HR = 2.01; P = 0.02 for first-available SBP
model; HR = 2.04; P = 0.02 for average-of-first-two SBP
model), age (HR = 1.05; P < 0.0001) and SLEDAI-2K
(HR = 1.03; P = 0.01) at baseline, and steroid use ever
(HR = 2.73 for first available and 2.74 for average of
first two SBPs, P = 0.03) were significantly associated
with a CAD event. Antimalarial use ever was protective
against CAD (HR = 0.59; P = 0.02). Disease duration,
elevated TC, and immunosuppressive use at baseline
were not significantly associated with CAD.
In time-dependent models (Table 5, columns 3 to 5
inclusive), mean (HR = 1.025; P = 0.004) and AM (HR =
1.024; P = 0.004) SBP at each visit were significantly
associated with a CAD event, with the same HR for
each of these summary measures of SBP. In these mod-
els, other significant covariates included male sex (HR =
1.87; P = 0.04, for recent SBP model), age (HR = 1.06; P
< 0.0001 for most recent SBP, HR = 1.04; P < 0.0001 for
mean and AM SBP), SLEDAI-2K score (HR = 1.09; P <
0.0001 for all three models), and elevated cholesterol
(HR = 1.72 for most recent,1 . 6 8f o rmean, and 1.69 for
AM SBP; P = 0.03 for all three models) at each visit.
AUC SBP (Table 5, last column) was not significantly
associated with CAD.
DBP models
Results of the proportional hazards models for CAD
outcomes using various measures of diastolic blood
pressure (DBP) were similar to the SBP models and are
presented in Table 6.
In each of the multiple regression analyses presented
in Tables 3 through 6, antiphospholipid antibodies, dia-
betes, and smoking were consistently statistically insig-
nificant and therefore removed from the final models to
maximize statistical power. Data on antihypertensive use
and lipid-lowering therapy were incomplete for a pro-
portion of visits. In subgroup analysis of these smaller
datasets, neither antihypertensives nor lipid-lowering
medications were significantly associated with CAD
events (data not shown).
Discussion
Through the use of proportional hazards regression
modeling in a large sample of more than 950 patients,
Nikpour et al. Arthritis Research & Therapy 2011, 13:R156
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Page 7 of 14Table 3 Proportional hazards models for coronary outcomes using various measures of cholesterol
Time-constant models Time-dependent models
First available ("remote”) TC Average of
first two TCs
Most recent TC Mean TC Time-adjusted
mean TC
AUC TC
HR
(95% CI)
P HR
(95% CI)
P HR
(95% CI)
P HR
(95% CI)
P HR
(95% CI)
P HR
(95% CI)
p
Cholesterol (TC) 1.07
(0.93, 1.22)
0.36 1.08
(0.94, 1.24)
0.30 1.22
(1.05, 1.42)
0.01 1.22
(1.01, 1.47)
0.04 1.22
(1.02, 1.47)
0.03 1.00
(1.00, 1.00)
0.29
Male sex 2.02
(1.12, 3.62)
0.02 2.00
(1.11, 3.59)
0.02 1.84
(1.02, 3.32)
0.04 1.75
(0.97, 3.18)
0.06 1.74
(0.96, 3.15)
0.07 1.78
(0.98, 3.23)
0.06
Age
ψ 1.06
(1.04, 1.08)
< 0.0001 1.06
(1.04, 1.08)
< 0.0001 1.06
(1.05, 1.08)
< 0.0001 1.06
(1.05, 1.08)
< 0.0001 1.06
(1.04, 1.08)
< 0.0001 1.06
(1.04, 1.08)
< 0.0001
SLEDAI-2K
¶ 1.03
(1.001, 1.06)
0.04 1.03
(1.00, 1.06)
0.06 1.09
(1.05, 1.13)
< 0.0001 1.09
(1.05, 1.13)
< 0.0001 1.09
(1.05, 1.13)
< 0.0001 1.09
(1.05, 1.13)
< 0.0001
Hypertension
¢ 1.12
(0.61, 2.04)
0.72 1.10
(0.60, 2.02)
0.76 1.50
(0.93, 2.42)
0.095 1.57
(0.97, 2.52)
0.06 1.57
(0.98, 2.52)
0.06 1.67
(1.05, 2.67)
0.03
Corticosteroids
b 4.17
(1.62, 10.73)
0.003 4.16
(1.62, 10.72)
0.003 1.85
(1.05, 3.23)
0.03 1.89
(1.08, 3.30)
0.03 1.89
(1.08, 3.30)
0.03 1.92
(1.10, 3.35)
0.02
Antimalarials
§ 0.50
(0.31, 0.79)
0.003 0.50
(0.31, 0.80)
0.004 0.90
(0.57, 1.44)
0.66 0.88
(0.55, 1.41)
0.59 0.88
(0.55, 1.41)
0.60 0.80
(0.51, 1.27)
0.35
Immunosuppressives
¥ 0.79
(0.49, 1.26)
0.32 0.78
(0.49, 1.25)
0.30 1.32
(0.82, 2.14)
0.25 1.29
(0.79, 2.08)
0.31 1.29
(0.79, 2.09)
0.31 1.34
(0.83, 2.17)
0.23
95% CI, 95% confidence interval; AUC, area under the curve; BP, blood pressure (mm Hg); DBP, diastolic blood pressure (mm Hg); HR, hazard ratio; NS: not significant; P, P value; SBP, systolic blood pressure (mm Hg);
TC, total plasma cholesterol (mmol/L).
ψYears; age at the time of first available TC (or SBP or DBP) in time-constant models and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
¶SLE Disease Activity Index
2000; scores range from 0 to 105, with higher scores indicating more-active disease; measured at the time of first available TC (or SBP or DBP) in time-constant models, and coincident with each TC (or SBP or DBP)
measurement in the time-dependent covariate models.
¢Hypertension defined as diastolic BP ≥90 or systolic BP ≥140 mm Hg; defined as present ever during the study in time-constant models, and coincident with
each TC measurement in the time-dependent covariate models.
bCorticosteroids defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the
time-dependent covariate models.
ζElevated total plasma cholesterol (hypercholesterolemia) defined as total plasma cholesterol > 5.2 mmol/L; measured at the time of first available SBP or DBP in time-constant
models, and coincident with each SBP or DBP measurement in the time-dependent covariate models.
§Antimalarials include chloroquine and hydroxychloroquine; defined as used ever during the study in time-
constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
¥Immunosuppressives include methotrexate, azathioprine, mycophenolate mofetil, cyclosporine,
and cyclophosphamide; defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
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4in whom collectively more than 18, 000 serial measure-
ments of TC and BP were taken over a mean duration
of 6.3 years, we were able to demonstrate and quantify
the association between several important risk factors
and CAD events in SLE.
Foremost, this study highlights the important role of
traditional risk factors such as elevated TC and BP in
SLE-related CAD and demonstrates a continuum of risk
associated with these variables across the range of possi-
ble values they may assume. Previous studies have
shown that traditional risk factors, such as hypercholes-
terolemia and hypertension, account for only a small
proportion of the increased risk of CAD in SLE. How-
ever, in these studies, TC and BP were measured at
baseline, in keeping with the premise of the Framing-
ham model. Here we have shown that this remote mea-
sure of exposure to TC, SBP, or DBP is not predictive
of CAD outcome among patients with SLE. Further-
more, recent measurements of TC and BP, which are
also taken at a single point in time, are not able to
quantify CAD risk to the same degree as “summary
measures, “ which capture cumulative exposure to these
risk factors over the course of disease. We have pre-
viously shown that, unlike the general population,
wherein TC and BP “track” over time, in patients with
SLE, these risk factors take a dynamic course, varying
because of changes in disease activity and treatment [5].
In this study, cumulative exposure to TC, SBP, and
DBP was measured by using three summary measures,
arithmetic mean, time-adjusted mean (AM), and area-
under-the-curve (AUC). Time-dependent proportional
hazards regression models were then applied to these
summary measures. In this way, a sense of cumulative
exposure was captured in two ways: first, in the form of
a summary measure, and second, by determining the
hazard related to this summary measure for an interval
just before each and every sequential visit. In these
time-dependent models, a sense of cumulative exposure
to other covariates, including disease activity score, cor-
ticosteroids, and antimalarials, was also captured
through the use of serial measurements of these vari-
ables, updated from one visit to the next.
For each of TC, SBP, and DBP, mean and AM sum-
mary measures were significantly predictive of a CAD
event. In addition, the HR and accompanying P value of
mean summary measures was the same as for AM sum-
mary measures in the case of each of TC, SBP, and
DBP. This is likely related to the fact that overall, in this
context, in which measurements were taken frequently,
mean and AM values were very similar for each patient.
However, when applied to a setting in which measure-
ments are more irregular and infrequent, the AM, which
is weighted for the interval between measurements, may
be expected more accurately to reflect cumulative risk
Table 4 Proportional hazards models for coronary outcomes using various measures of cholesterol, including only
significant covariates in the models
Time-dependent covariate models
Most recent TC Mean TC Time-adjusted
mean TC
HR
(95% CI)
P HR
(95% CI)
P HR
(95% CI)
P
Cholesterol (TC) 1.86
(1.30, 2.68)
0.001 2.07
(1.28, 3.36)
0.003 2.07
(1.28, 3.34)
0.003
Male sex 1.90
(1.06, 3.41)
0.03 1.83
(1.01, 3.29)
0.046 1.82
(1.01, 3.29)
0.047
Age
ψ 1.12
(1.07, 1.17)
< 0.0001 1.13
(1.06, 1.20)
< 0.0001 1.13
(1.06, 1.20)
< 0.0001
SLEDAI-2K
¶ 1.09
(1.05, 1.13)
< 0.0001 1.10
(1.06, 1.14)
< 0.0001 1.10
(1.06, 1.14)
< 0.0001
Corticosteroids
b 2.04
(1.20, 3.45)
0.01 2.01
(1.19, 3.41)
0.01 2.01
(1.19, 3.41)
0.01
95% CI, 95% confidence interval; AUC, area under the curve; BP, blood pressure (mm Hg); DBP: diastolic blood pressure (mm Hg); HR, hazard ratio; NS, not
significant; P, P value; SBP, systolic blood pressure (mm Hg); TC, total plasma cholesterol (mmol/L).
ψYears; age at the time of first available TC (or SBP or DBP) in time-constant models and coincident with each TC (or SBP or DBP) measurement in the time-
dependent covariate models.
¶SLE Disease Activity Index 2000; scores range from 0 to 105, with higher scores indicating more-active disease; measured at the
time of first available TC (or SBP or DBP) in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate
models.
¢Hypertension defined as diastolic BP ≥ 90 or systolic BP ≥ 140 mm Hg; defined as present ever during the study in time-constant models, and
coincident with each TC measurement in the time-dependent covariate models.
bCorticosteroids defined as used ever during the study in time-constant models,
and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
ζElevated total plasma cholesterol (hypercholesterolemia)
defined as total plasma cholesterol > 5.2 mmol/L; measured at the time of first available SBP or DBP in time-constant models, and coincident with each SBP or
DBP measurement in the time-dependent covariate models.
§Antimalarials include chloroquine and hydroxychloroquine; defined as used ever during the study in
time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
¥Immunosuppressives include
methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, and cyclophosphamide; defined as used ever during the study in time-constant models, and
coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
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Page 9 of 14Table 5 Proportional hazards models for coronary events using various measures of systolic blood pressure
Time-constant models Time-dependent models
First available ("remote”) SBP Average of
first two SBP
Most recent SBP Mean SBP Time-adjusted
mean SBP
AUC SBP
HR
(95% CI)
P HR
(95% CI)
P HR
(95% CI)
P HR
(95% CI)
P HR
(95% CI)
P HR
(95%)I)
p
Systolic blood pressure (SBP) 1.00
(0.99, 1.02)
0.45 1.31
(0.68, 2.53)
0.42 1.01
(1.00, 1.02)
0.052 1.025
(1.01, 1.04)
0.004 1.024
(1.01, 1.04)
0.004 1.00
(1.00, 1.00)
0.19
Male sex 2.01
(1.13, 3.59)
0.02 2.04
(1.14, 3.65)
0.02 1.87
(1.03, 3.39)
0.04 1.75
(0.96, 3.21)
0.07 1.74
(0.95, 3.18)
0.07 1.83
(1.00, 3.33)
0.049
Age
ψ 1.05
(1.03, 1.07)
< 0.0001 1.05
(1.03, 1.07)
< 0.0001 1.06
(1.03, 1.07)
< 0.0001 1.04
(1.02, 1.07)
< 0.0001 1.04
(1.02, 1.07)
< 0.0001 1.06
(1.04, 1.08)
< 0.0001
SLEDAI-2K
¶ 1.03
(1.01, 1.06)
0.01 1.03
(1.01, 1.06)
0.01 1.09
(1.05, 1.13)
< 0.0001 1.09
(1.05, 1.13)
< 0.0001 1.09
(1.05, 1.13)
< 0.0001 1.09
(1.05, 1.13)
< 0.0001
Elevated cholesterol
ζ 1.41
(0.67, 2.98)
0.37 1.39
(0.66, 2.95)
0.39 1.72
(1.06, 2.78)
0.03 1.68
(1.04, 2.71)
0.03 1.69
(1.04, 2.73)
0.03 1.82
(1.13, 2.92)
0.01
Corticosteroids
b 2.73
(1.13, 6.61)
0.03 2.74
(1.13, 6.62)
0.03 1.74
(0.99, 3.08)
0.06 1.72
(0.98, 3.03)
0.06 1.72
(0.97, 3.03)
0.06 1.77
(1.00, 3.12)
0.049
Antimalarials
§ 0.59
(0.37, 0.93)
0.02 0.59
(0.37, 0.95)
0.03 0.95
(0.60, 1.52)
0.84 0.97
(0.61, 1.56)
0.91 0.97
(0.61, 1.55)
0.89 0.93
(0.58, 1.48)
0.75
Immunosuppressives
¥ 0.91
(0.58, 1.43)
0.68 0.89
(0.56, 1.41)
0.63 1.51
(0.93, 2.45)
0.10 1.48
(0.91, 2.40)
0.11 1.48
(0.91, 2.40)
0.11 1.46
(0.90, 2.36)
0.13
95% CI: 95% confidence interval; AUC: area under the curve; BP: blood pressure (mmHg); DBP: diastolic blood pressure (mmHg); HR: hazard ratio; NS: not significant; p: p value; SBP: systolic blood pressure (mmHg);
TC: total plasma cholesterol (mmol/L).
ψYears; age at the time of first available TC (or SBP or DBP) in time-constant models and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
¶SLE Disease Activity Index
2000; scores range from 0 to 105, with higher scores indicating more active disease; measured at the time of first available TC (or SBP or DBP) in time-constant models, and coincident with each TC (or SBP or DBP)
measurement in the time-dependent covariate models.
¢Hypertension defined as Diastolic BP ≥ 90 or Systolic BP ≥ 140 mmHg; defined as present ever during the study in time-constant models, and coincident with
each TC measurement in the time-dependent covariate models.
bCorticosteroids defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the
time-dependent covariate models.
ζElevated total plasma cholesterol (Hypercholesterolemia) defined as total plasma cholesterol > 5.2 mmol/L; measured at the time of first available SBP or DBP in time-constant
models, and coincident with each SBP or DBP measurement in the time-dependent covariate models.
§Antimalarials include chloroquine and hydroxychloroquine; defined as used ever during the study in time-
constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
¥Immunosuppressives include methotrexate, azathioprine, mycophenolate mofetil, cyclosporine
and cyclophosphamide; defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
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4Table 6 Proportional hazards models for coronary events using various measures of diastolic blood pressure
Time-constant models Time-dependent models
First available (’remote’) DBP Average of
first two DBP
Most recent DBP Mean DBP Time-adjusted
mean DBP
AUC DBP
HR
(95% CI)
p HR
(95% CI)
p HR
(95% CI)
p HR
(95% CI)
p HR
(95% CI)
p HR
(95% CI)
p
Diastolic blood pressure (DBP) 1.00
(0.98, 1.02)
0.87 1.01
(0.99, 1.03)
0.46 1.02
(1.003, 1.05)
0.02 1.04
(1.01, 1.07)
0.02 1.04
(1.01, 1.07)
0.02 1.00
(1.00, 1.00)
0.94
Male sex 2.01
(1.13, 3.60)
0.02 2.00
(1.12, 3.58)
0.02 1.85
(1.02, 3.36)
0.04 1.72
(0.94, 3.15)
0.08 1.70
(0.93, 3.11)
0.09 1.88
(1.03, 3.43)
0.039
Age
ψ 1.05
(1.04, 1.07)
< 0.0001 1.05
(1.04, 1.07)
< 0.0001 1.06
(1.04, 1.08)
< 0.0001 1.06
(1.04, 1.08)
< 0.0001 1.06
(1.04, 1.07)
< 0.0001 1.06
(1.04, 1.08)
< 0.0001
SLEDAI-2K
¶ 1.03
(1.01, 1.06)
0.01 1.03
(1.01, 1.06)
0.01 1.09
(1.05, 1.13)
< 0.0001 1.09
(1.05, 1.13)
< 0.0001 1.09
(1.05, 1.13)
< 0.0001 1.09
(1.05, 1.13)
< 0.0001
Elevated cholesterol
ζ 1.42
(0.67, 3.00)
0.36 1.40
(0.66, 2.96)
0.38 1.70
(1.05, 2.74)
0.03 1.70
(1.06, 2.75)
0.03 1.69
(1.04, 2.73)
0.03 1.86
(1.16, 2.99)
0.01
Corticosteroids
b 2.81
(1.16, 6.80)
0.02 2.74
(1.13, 6.63)
0.03 1.75
(0.99, 3.10)
0.054 1.76
(1.00, 3.11)
0.051 1.72
(0.97, 3.03)
0.06 1.81
(1.02, 3.19)
0.04
Antimalarials
§ 0.57
(0.36, 0.90)
0.02 0.59
(0.37, 0.94)
0.03 0.95
(0.60, 1.51)
0.82 0.96
(0.60, 1.53)
0.85 0.96
(0.60, 1.53)
0.85 0.92
(0.58, 1.47)
0.73
Immunosuppressives
¥ 0.91
(0.58, 1.43)
0.68 0.89
(0.56, 1.41)
0.61 1.45
(0.89, 2.34)
0.13 1.37
(0.85, 2.23)
0.20 1.38
(0.85, 2.23)
0.20 1.43
(0.88, 2.32)
0.14
95% CI: 95% confidence interval; AUC: area under the curve; BP: blood pressure (mmHg); DBP: diastolic blood pressure (mmHg); HR: hazard ratio; NS: not significant; p: p value; SBP: systolic blood pressure (mmHg);
TC: total plasma cholesterol (mmol/L).
ψYears; age at the time of first available TC (or SBP or DBP) in time-constant models and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
¶SLE Disease Activity Index
2000; scores range from 0 to 105, with higher scores indicating more active disease; measured at the time of first available TC (or SBP or DBP) in time-constant models, and coincident with each TC (or SBP or DBP)
measurement in the time-dependent covariate models.
¢Hypertension defined as Diastolic BP ≥ 90 or Systolic BP ≥ 140 mmHg; defined as present ever during the study in time-constant models, and coincident with
each TC measurement in the time-dependent covariate models.
bCorticosteroids defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the
time-dependent covariate models.
ζElevated total plasma cholesterol (Hypercholesterolemia) defined as total plasma cholesterol > 5.2 mmol/L; measured at the time of first available SBP or DBP in time-constant
models, and coincident with each SBP or DBP measurement in the time-dependent covariate models.
§Antimalarials include chloroquine and hydroxychloroquine; defined as used ever during the study in time-
constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
¥Immunosuppressives include methotrexate, azathioprine, mycophenolate mofetil, cyclosporine
and cyclophosphamide; defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
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4exposure and hence the overall risk of CAD. In the case
of TC, a hazard ratio of 2.07 (P = 0.003) means that for
every 1 mmol/L increase in mean (or AM) plasma TC
level, the hazard of a CAD outcome increases 2.07-fold.
In the case of SBP, a hazard ratio of 1.025 means that
for every 1-mm Hg increase in mean SBP, the hazard of
CAD outcome increases 1.025-fold.
Likewise, in the case of DBP,ah a z a r dr a t i oo f1 . 0 4
means that for every 1-mm Hg increase in mean (or
AM) DBP, the hazard of CAD outcome increases 1.04-
fold. SBP and DBP are highly correlated, and, based on
our analyses, either one or the other may be used to
quantify CAD risk in patients with SLE.
AUC is very closely tied to length of follow-up, and
for any given variable may only become larger over
time. As such, it does not provide a sense of rise and
fall in the variable of interest. Furthermore, it is not
measured in the original units of the variable from
which it is derived. These reasons may underlie the lack
of association between AUC measures and CAD out-
comes among SLE patients in our study.
In this proof-of-concept study, our chosen lipid mar-
ker of CAD risk was TC. In general, low-density lipo-
protein cholesterol (LDL-C) is deemed the primary
target of lipid-lowering therapy [11]. In the Toronto
lupus cohort, measurement of nonfasting TC has been
routine practice at every visit since 1975. However, mea-
surement of lipid and lipoprotein subfractions is a more-
recent addition to the data-collection protocol and per-
formed only once yearly because of the need for a fast-
ing sample. To derive summary measures and test their
ability to quantify CAD risk, we required a very large
dataset inclusive of a relatively large number of CAD
outcomes. The TC and BP datasets fulfilled these meth-
odologic requirements. In future, summary measures
derived in this study may be applied to other risk fac-
tors, such as LDL-C.
How many measurements are enough to provide a
valid summary measure, and how often should these
measurements be taken in patients with SLE? In this
study, the average of first two TC (or SBP or DBP) mea-
surements was not significantly predictive of CAD out-
come. Therefore, ideally three or more serial
measurements should be sought. Although in this study,
the mean gap between measurements used to calculate
summary measures was 4.3 months, patients in whom
the gap between one or more serial measurements
exceeded 18 months were not included in the analyses.
Further studies are required to determine the optimal
number and frequency of measurements of TC and BP
in evaluating CAD risk in SLE.
This study has provided several important insights
into the role of demographic-, disease-, and treatment-
related variables in SLE-related CAD. The most
noteworthy are the increased risk of CAD with increas-
ing disease activity and corticosteroid use, and the pro-
tective effect of antimalarials.
We found that for every unit increase in recent SLE-
DAI-2K disease activity score, the risk of CAD event by
the time of the subsequent visit increased almost 10%.
An increase in SLEDAI-2K score of 4 or more is gener-
ally deemed clinically significant [12]. This means that a
minimum clinically significant increase in recent disease
activity score is associated with approximately 46%
increase in risk of CAD in the interval between sequen-
tial visits. Ibanez et al.[ 1 3 ]p r e v i o u s l ys h o w e dt h a tf o r
every unit increase in the time-adjusted mean SLEDAI-
2K score (AMS), the hazard of a CAD outcome
increases 1.08-fold. Collectively, these associations high-
light the underpinning role of inflammation in SLE-
related CAD.
Our patients with CAD events had greater disease
activity at baseline and during follow-up, manifest in a
multitude of organ systems, including musculoskeletal,
cutaneous, renal, neural, vascular, and serosal. As the
overall prevalence of chronic renal impairment was low
and did not differ among groups with and without
CAD, the association between disease activity and events
seen in this study cannot be attributed to nephritis or
renal impairment alone.
In studies of coronary risk factors in SLE, it is often
difficult to tease apart the effect of corticosteroids from
disease activity and traditional cardiac risk factors. In
previous studies, longer duration of steroid use has been
shown to be an independent risk factor for CAD in SLE
[1,14]. With a retrospective chart review method, Karp
et al.[ 1 5 ]s h o w e dt h a ta1 0 - m gi n c r e a s ei nt h ea v e r a g e
daily prednisone-equivalent dose in the preceding year
is independently associated with a 16% increase in the
estimated 2-year CAD risk. Here, we quantified the
CAD risk in patients with SLE by using prospectively
collected data. Patients with CAD events received a sig-
nificantly greater cumulative dose of corticosteroids dur-
ing follow-up than did those who remained CAD free.
In the regression models for first-available and average-
of-first-two TC levels, exposure to corticosteroids at any
time during the course of disease, irrespective of dose
and duration of use, was associated with a dramatic
4.17-fold increased risk of a CAD event, independent of
other risk factors. This HR was reduced to 1.85, but
remained substantial and statistically significant, in the
time-dependent models wherein recent exposure to cor-
ticosteroids was related to a CAD event.
In time-constant models for TC and BP, antimalarial
use during the course of SLE was associated with a
remarkable 50% to 59% reduction in hazard of a CAD
event. The lack of a significant association between
recent antimalarial use and CAD in the time-dependent
Nikpour et al. Arthritis Research & Therapy 2011, 13:R156
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Page 12 of 14models may point to a beneficial effect with long-term
rather than short-term use. In previous studies, use of
antimalarials has been associated with a reduction in TC
level [5,14,16,17]. However, ours is one of only a few
studies in which the use of antimalarials has been linked
with a reduction in the risk of actual CAD events
[18,19]. Furthermore, the halving of coronary risk makes
a strong case for the use of antimalarials in patients
with SLE, not only to control disease activity but also
for cardioprotection.
As in previous studies, we have shown that male sex
and older age are associated with increased hazard of a
CAD event. In previous studies, anti-phospholipid anti-
bodies, diabetes, and smoking were shown to be inde-
pendent risk factors for CAD events in SLE [20].
However, in this study, in multiple regression analysis,
such an association was not found, possibly because of
the limited number of patients who smoke or have dia-
betes or anti-phospholipid antibodies. This study is not
an exhaustive evaluation of traditional risk factors, and
the role of other variables, such as family history of
ischemic heart disease, body mass index (BMI), and
waist/hip ratio, merit further investigation in future
studies.
In summary, we showed that elevated TC and BP are
both potentially treatable risk factors for CAD in SLE.
Our study highlighted the importance of frequent mea-
surements of BP and TC in management of patients
with SLE. Although clinicians might consider the need
for change in treatment based on single TC and BP
measurements, their decision actually to do so should
be made on the basis of the mean of several
measurements.
Conclusions
Overall, this study has both conceptual and practical
significance. From a conceptual point of view, our
findings illustrate that in a systemic inflammatory dis-
ease, for a dynamic risk factor such as TC or BP, sum-
mary measures such as mean and AM better reflect
cumulative exposure and hence better quantify CAD
r i s k .T h i si sa ni m p o r t a n tc o nsideration in future stu-
dies of dynamic risk factors for CAD in a chronic
relapsing-remitting disease such as SLE and may be
used to derive risk-prediction models specifically for
SLE. From a practical point of view, this study has
shown that assessment of coronary risk related to TC
and BP in patients with SLE relies on serial measure-
ment of these risk factors throughout the relapsing-
remitting course of SLE. Additionally, this study has
shown that disease activity and corticosteroid use are
CAD risk factors in SLE, indicating that disease activity
should be recognized and optimally controlled by using
the minimal effective dose of corticosteroids. The
demonstration of a cardioprotective association of anti-
malarials highlights the staple role of this class of
drugs in the management of patients with SLE. Finally,
this study has quantified the risk associated with expo-
sure to TC, SBP, and DBP over time, emphasizing the
importance of these potentially treatable traditional
risk factors in patients with SLE. Future efforts must
be directed toward determining TC and BP cut-points
for CAD risk stratification specifically among patients
with SLE and the role of treatment of risk factors in
reducing the incidence of CAD events.
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